Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
4.120
-0.010 (-0.24%)
At close: Oct 2, 2026, 4:00 PM EDT
4.115
-0.005 (-0.12%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
The company was founded in 2010 and is based in Glen Allen, Virginia.
Adial Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Cary Claiborne |
Contact Details
Address: 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 United States | |
| Phone | 804 487 8196 |
| Website | adial.com |
Stock Details
| Ticker Symbol | ADIL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 00688A304 |
| ISIN Number | US00688A3041 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cary John Claiborne MBA | Chief Executive Officer, President and Director |
| Vinay Shah A.C.A., C.P.A., M.B.A. | Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 2, 2026 | 8-K | Current Report |
| Sep 18, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 16, 2026 | 8-K | Current Report |
| Aug 28, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 28, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 24, 2026 | ARS | Filing |
| Aug 24, 2026 | DEF 14A | Other definitive proxy statements |